Adecatumumab is a human IgG1 monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM). EpCAM is expressed in almost all adenocarcinomas and its activity is not dependent of K-Ras status. Adecatumumab acts as a drug candidate for the treatment of cancers.